Itraconazole Sandoz Ltd

Itraconazole, the active ingredient in Itraconazole Sandoz Ltd, is an azole antifungal presented as an oral tablet for oral use. It treats a range of systemic and superficial fungal infections in adults and children as prescribed by a healthcare professional.

GNH USA supplies Itraconazole Sandoz Ltd as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazole is an azole antifungal used to manage infections caused by susceptible fungi. - Dermatophyte infections: effective for skin, nail and hair infections caused by dermatophytes. - Candidiasis: treats oral, esophageal and systemic Candida infections. - Blastomycosis: used for severe or disseminated Blastomyces dermatitidis infection. - Histoplasmosis: indicated for acute and chronic Histoplasma capsulatum disease. - Sporotrichosis: employed in the management of cutaneous and disseminated Sporothrix schenckii infection. - Aspergillosis: used for invasive disease caused by Aspergillus species.

Common side effects are generally mild and may resolve with continued therapy.

Common Side Effects: - Nausea - Vomiting - Abdominal pain or discomfort - Headache - Rash or pruritus - Altered taste sensation

Serious or Rare Side Effects: - Hepatotoxicity, including severe liver injury - Stevens‑Johnson syndrome or toxic epidermal necrolysis - Cardiac failure or reduced left‑ventricular function - Severe visual disturbances such as blurred vision - Neutropenia or other significant blood dyscrasias - Acute adrenal insufficiency

Before initiating therapy, consider the following precautions. - Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Evaluate cardiac status: use caution in patients with existing heart failure. - Review concomitant medications: avoid drugs that may prolong QT interval. - Monitor for drug‑induced skin reactions: discontinue if severe rash develops. - Store at room temperature: keep in the original container, protect from moisture and light.

Itraconazole has a notable potential for drug‑drug interactions due to CYP3A4 inhibition and induction.

Major Interactions (Avoid): - Rifampin: markedly reduces itraconazole plasma concentrations. - St. John's wort: induces metabolism, lowering efficacy. - Ketoconazole: additive hepatotoxic risk when combined. - Macrolide antibiotics (e.g., erythromycin): may increase itraconazole levels leading to toxicity. - Other azole antifungals (e.g., fluconazole): can cause excessive itraconazole exposure.

Moderate Interactions (Monitor Closely): - CYP3A4 substrates such as midazolam, calcium‑channel blockers, and certain statins. - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Proton‑pump inhibitors: can reduce absorption of itraconazole capsules. - Digoxin: increased serum concentrations may occur. - Antiretrovirals (e.g., protease inhibitors): may alter itraconazole levels.